Skip to main content
Fig. 1 | BMC Cardiovascular Disorders

Fig. 1

From: Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study

Fig. 1

Incidence of AEs, ADRs, thrombocytopenia and bleeding. Description of AEs (A), ADRs, thrombocytopenia and bleeding (B) in Chinese STEMI patients receiving PCI and bivalirudin as anticoagulant. AEs: adverse events; ADRs: adverse drug reactions; STEMI: ST-segment elevation myocardial infarction; PCI: percutaneous coronary intervention

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us